Sarcomas | Specialty

The OncLive Sarcomas/TGCT condition center page is a comprehensive resource for clinical news and expert insights on tenosynovial giant cell tumor (TGCT), soft tissue sarcoma, gastrointestinal stromal tumor, Ewing sarcoma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in sarcomas and TGCT.

Dr. Turaga Discusses Current Surgical Setting of Sarcoma

May 8th 2017

Kiran Turaga, MD, MPH, surgical oncologist, University of Chicago Cancer Center, discusses the current surgical setting of sarcoma.

The Long-Term Potential of Olaratumab in Soft Tissue Sarcoma

May 8th 2017

Symantha Melemed, global product team lead, Oncology Business Unit, Eli Lilly & Company, discusses the impact of the FDA approval of olaratumab (Lartruvo) in patients with soft tissue sarcoma

Dr. George on Efficacy With PD-1 Inhibitor in Uterine Leiomyosarcoma

May 2nd 2017

Suzanne George, MD, assistant professor of Medicine, Harvard Medical School, clinical director, Center for Sarcoma and Bone Oncology, Dana-Farber Cancer Institute, discusses a study exploring the efficacy of a PD-1 inhibitor in patients with uterine leiomyosarcoma.

Comprehensive Genomic Profiling Could Improve Diagnoses, Treatment in Sarcoma

April 27th 2017

Researchers at MD Anderson Cancer Center believe that including clinical genomic profiling into sarcoma management could result in more precise diagnosis and subclassification of the disease.

Exceptional Responder to Pembrolizumab Guides Immunotherapy Progress in Leiomyosarcoma

April 24th 2017

Suzanne George, MD, discusses an exceptional responder to pembrolizumab in leiomyosarcoma and the significance of these findings for further immunotherapy advances in the field.

Dr. Wilky on Immunotherapy Trial in Sarcoma

April 13th 2017

Breelyn Wilky, MD, an associate professor of Medicine, Sylvester Comprehensive Cancer Care, University of Miami Health System, discusses the design of a phase II trial investigating concurrent axitinib (Inlyta) and pembrolizumab (Keytruda) in patients with advanced alveolar soft part sarcoma and other soft tissue sarcomas.

Survivors of Ewing Sarcoma Appear to Have Only Minor Long-Term Limitations

April 13th 2017

Researchers concluded that survivors of Ewing sarcoma are largely free of physical limitations and there is little apparent difference between survivors and healthy people in terms of mental health.

Dr. Gordon on Toxicities With Immunotherapy in Osteosarcoma

April 12th 2017

Nancy Gordon, MD, a pediatric oncologist and research assistant at The University of Texas MD Anderson Cancer Center, discusses toxicities associated with immunotherapy agents for the treatment of patients with osteosarcoma.

Dr. Sankhala on the Significance of TRC105/Pazopanib in Angiosarcoma

April 10th 2017

Kumar Sankhala, MD, medical director of Clinical Research, Sarcoma Oncology Center, discusses the significance of the combination of the endoglin antibody TRC105 plus pazopanib (Votrient) in patients with angiosarcoma.

Dr. Pollack on the Future Treatment Landscape for Sarcoma

April 8th 2017

Seth M. Pollack, assistant professor, Division of Oncology, University of Washington, and attending physician, Seattle Cancer Care Alliance, discusses the future treatment paradigm of soft tissue sarcoma.

A Call for Molecular Profiling in Uterine Carcinosarcoma

March 22nd 2017

Douglas Levine, MD, discusses a recent study in uterine carcinosarcoma and early steps toward developing therapeutic regimens.

Chemotherapy Approach Avoids Amputation in Sarcoma Patients

March 22nd 2017

John E. Mullinax, MD, discusses isolated limb infusion as a limb salvage strategy for locally advanced extremity sarcoma.

Dr. Wilky on Ongoing Trial of Pembrolizumab and Axitinib in Sarcoma

March 21st 2017

Breelyn Wilky, MD, an associate professor of Medicine, Sylvester Comprehensive Cancer Care, University of Miami Health System, discusses the status of a phase II trial investigating concurrent axitinib (Inlyta) and pembrolizumab (Keytruda) in patients with advanced alveolar soft part sarcoma and other soft tissue sarcomas.

Dr. Blay Discusses the Treatment Landscape of Sarcoma

March 21st 2017

Jean-Yves Blay, MD, PhD, professor of medicine at the Université Claude Bernard, Lyon, France, and the scientific director of the Canceropole Lyon Rhône Alpes, discusses the treatment landscape of sarcoma.

Dr. Kasper on Imatinib Versus Sorafenib in Sarcoma

March 18th 2017

Bernd Kasper, MD, PhD, professor, Universitätsmedizin Mannheim, Mannheim, discusses imatinib (Gleevac) versus sorafenib (Nexavar) as treatments for patients with sarcoma.

Dr. Albertsmeier on Radiotherapy Improving the Local Control of Sarcoma

March 17th 2017

Markus Albertsmeier, MD, surgeon, Ludwig Maximilian University of Munich, discusses radiotherapy improving the local control for patients with sarcoma.

Dr. Gordon on Next Steps With Immunotherapy Research in Osteosarcoma

March 15th 2017

Nancy B. Gordon, MD, assistant professor, Department of Pediatrics, The University of Texas MD Anderson Center, discusses next steps for immunotherapy research in the field of osteosarcoma.

Dr. Grignani Discusses the Safety Profile of Trabectedin in Sarcoma

March 10th 2017

Giovanni Grignani, MD, medical oncologist, Candiolo Cancer Institute IRCCS, discusses the safety profile of trabectedin (Yondelis) in the treatment of sarcoma.

Dr. Gordon on Immunotherapy Research in Osteosarcoma

March 3rd 2017

Nancy Gordon, MD, a pediatric oncologist and research assistant at The University of Texas MD Anderson Cancer Center, discusses current immunotherapy research being conducted in the field of osteosarcoma.

Novel Compound GPX-150 Shows Promise in Soft Tissue Sarcoma

February 23rd 2017

Brian Van Tine, MD, PhD, discusses the potential of the investigational compound 5-imino-13-deoxydoxorubicin (GPX-150) in metastatic and nonresectable soft tissue sarcoma.